KRAS and cancer: He then was continued on maintenance 5-fluorouracil plus capecitabine-based chemotherapy for 5 months after which time his cancer progressed and a liquid biopsy at that time revealed a KRAS Q61H mutation which was felt to be acquired from prior therapy with cetuximab.